Document text
Principal Investigator: Nitesh K Kunda
Organization: ST. JOHN'S UNIVERSITY
Fiscal Year: 2024
Award: $164,000
Funding agency: National Institute of General Medical Sciences
Summary
Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) is a highly infectious virus
known to cause the 2019 coronavirus disease (COVID-19). The disease has been declared as a
global pandemic by the World Health Organization. In the United States, as of January 20, 2021,
we have more than 24 million infected individuals with approximately 400,000 deaths. COVID-19
appears to be more deadly in patients with co-morbidities such as hypertension and diabetes and
presents many clinical manifestations such as pneumonia, diarrhea, multiple organ failure, etc.
among those infected. Moreover, the number of infections and fatality rate is expected to increase
significantly over the next few months, according to the IHME model. There is an urgent global
need to develop a thermostable and self-administrable vaccine. The spike protein on the surface
of coronavirus is an excellent candidate for developing vaccines, has been used in the currently
EUA obtained vaccines, as it plays an important role in the entry of the virus into the host cell.
Liposomes are excellent drug delivery systems that can present the antigen as particulate in
nature and allow the incorporation of an adjuvant that aids in the generation of a robust immune
response. Further, the liposomes can be designed to be of similar size to that of the virus and the
spike protein can be conjugated to the liposomal surface to mimic the natural presentation on the
virus. The immune cells will internalize and process the antigen like the virus and generate
neutralizing antibody titers. Most of the vaccines currently in the market require cold chain
(refrigeration) to store and distribute the vaccine to maintain the efficacy and require a visit to the
clinic for immunization by trained medical personnel. These serve as bottlenecks in achieving
mass vaccination in a pandemic adding further stress to the hospitals and the supply chain. In
addition, a major limitation is the limited ability of existing manufacturing facilities to manufacture
billions of doses. In this proposal, we aim to develop a thermostable and inhalable dry powder
vaccine that is easy to scale-up, eliminates the need for cold-chain storage and transport, and is
self-administrable by individuals’ at-home by simple inhalation. To achieve this goal, we will
pursue two aims: 1) Formulation of an inhalable and thermostable dry powder COVID-19 vaccine
containing S protein-adsorbed liposomal carriers and 2) Evaluation of neutralizing mucosal and
systemic IgA and IgG antibody titers after aerosol administration of dry powder COVID-19 vaccine
in mice. Successful completion of this project will have a profound impact on the development of
dry powder COVID-19 vaccine, particularly in exploring thermostable and inhalable vaccines that
are easy to manufacture, store, and distribute, characteristics that are critical in pandemic.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><7S Gamma Globulin><ACE2><Acute><Adjuvant><Adsorption><Aerosols><Affect><Animal Model><Animal Models and Related Studies><Antibodies><Antibody Response><Antibody titer measurement><Antigen Presentation><Antigen-Presenting Cells><Antigens><Assay><Bioassay><Biological Assay><COVID-19><COVID-19 infection><COVID-19 vaccine><COVID-19 virus><COVID-19 virus infection><COVID19 infection><COVID19 virus><CV-19><Cell Body><Cells><Cessation of life><Characteristics><Clinic><Clinical><CoV-2><CoV2><Cold Chains><Collaborations><Coronaviridae><Coronavirus><Coronavirus Infectious Disease 2019><Data><Death><Deposit><Deposition><Development><Diabetes Mellitus><Diarrhea><Disease><Disorder><Dose><Drug Delivery><Drug Delivery Systems><Dryness><Encapsulated><Epithelium><Evaluation><Exocrine IgA><Fatality rate><Formulation><Generations><Glycoproteins><Goals><Health Care Providers><Health Personnel><Healthcare Providers><Healthcare worker><Home><Hospitals><Hypertension><IgG><Immune><Immune response><Immunes><Immunization><Immunize><Immunoglobulin G><Immunological response><Individual><Infection><Inhalation><Inhaling><Intramuscular><LMIC><Liposomal><Liposomes><Lower respiratory tract structure><Lung><Lung Respiratory System><MOF syndrome><Marketing><Mass Vaccinations><Mediating><Membrane Fusion><Memory B Cell><Memory B-Lymphocyte><Mice><Mice Mammals><Modeling><Mucosa><Mucosal Tissue><Mucous Membrane><Multiple Organ Dysfunction Syndrome><Multiple Organ Failure><Murine><Mus><Nature><Organ><Particulate><Patients><Play><Pneumonia><Powder dose form><Powders><Process><Proteins><Publishing><RNA vaccine><RNA-based vaccine><Receptor Protein><Refrigeration><Respiration Disorders><Respiratory Disorder><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 infection><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SIgA><Secretory IgA><Secretory Immunoglobulin A><Self Administered><Self Administration><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Stress><Surface><System><T-Cells><T-Lymphocyte><Testing><Training><United States><Upper respiratory tract><Vaccination><Vaccines><Vascular Hypertensive Disease><Vascular Hypertensive Disorder><Virus><Visit><Work><World Health Organization><Wuhan coronavirus><accessory cell><angiotensin converting enzyme 2><angiotensin converting enzyme II><antibody titering><booster dose><booster shot><booster vaccine><breathing disorder><co-morbid><co-morbidity><comorbidity><corona virus><coronavirus disease 2019><coronavirus disease 2019 infection><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><deliver vaccines><deploy vaccines><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><diabetes><distribute vaccines><full scale manufacturing><hCoV19><health care personnel><health care worker><health provider><health workforce><healthcare personnel><high blood pressure><homes><host response><hyperpiesia><hyperpiesis><hypertensive disease><hypertensive disorder><immune system response><immunogen><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infection rate><large scale manufacturing><large scale production><liposomal carrier><liposomal delivery><liposomal nanocarrier><liposomal vehicle><liposome delivery><liposome vector><low and middle-income countries><lower respiratory tract><mRNA vaccine><mRNA-based vaccine><manufacture><manufacturing facility><manufacturing plants><mass production><medical personnel><method development><model of animal><multiorgan failure><multiple organ system failure><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><nano particle><nano-sized particle><nanoparticle><nanosized particle><neutralizing antibody><novel><oral vaccine><pandemic><pandemic disease><particle><pathogen><production plants><public health emergency><pulmonary><rate of infection><receptor><respiratory dysfunction><response><scale up><social role><supply chain><thermolability><thermostability><thymus derived lymphocyte><treatment provider><upper airway tract><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine boost><vaccine candidates against SARS-CoV-2><vaccine delivery><vaccine deployment><vaccine development><vaccine distribution><vaccine efficacy><vaccine for novel coronavirus><vaccine roll-out><vaccine rollout><vaccines preventing COVID><vaccines to prevent COVID><viral transmission><virus transmission>